GILEAD | Medical Information

Hepcludex® (bulevirtide-gmod) Clinical Practice Guidelines

This document is in response to your request for information regarding the use of Hepcludex® (bulevirtide-gmod [BLV]) for the treatment of chronic HDV infection and treatment guidelines from the American Association for the Study of Liver Diseases (AASLD), American Gastroenterological Association (AGA), European AIDS Clinical Society (EACS), and European Association for the Study of Liver (EASL).

Some data may be outside of the US FDA-approved prescribing information. In providing this data, Gilead Sciences, Inc. is not making any representation as to its clinical relevance or to the use of any Gilead product(s). For information about the approved conditions of use of any Gilead drug product, please consult the FDA-approved prescribing information.

This document includes content from or references to clinical practice guidelines, and inclusion of this information should not be interpreted as a treatment recommendation or an endorsement of the guidelines by Gilead Sciences, Inc.

The full indication, important safety information, and boxed warnings are available at: www.gilead.com/-/media/files/pdfs/medicines/hdv/hepcludex/hepcludex_pi.

Clinical Practice Guidelines on the Treatment of HDV

The most recent clinical practice guidelines are as follows:

- AASLD: Information on the prevention, diagnosis, and/or treatment of chronic HBV with consideration for those with HDV (www.aasld.org/publications/practice-guidelines)
- AGA: HDV guidelines (https://gastro.org/clinical-guidance/management-of-hepatitis-delta-virus/)
- EACS: Information on the the treatment of HIV, and include considerations for treatment of persons with viral hepatitis co-infections, including HDV (https://www.iasusa.org/tam/march-2024)
- EASL: HDV guidelines (https://easl.eu/publication-category/clinical-practice-guidelines/)

Product Label

For the full indication, important safety information, and boxed warning(s), please refer to the Hepcludex US Prescribing Information available at: www.gilead.com/-/media/files/pdfs/medicines/hdv/hepcludex/hepcludex_pi.

Follow-Up

For any additional questions, please contact Gilead Medical Information at:

☎1-866-MEDI-GSI (1-866-633-4474) or www.askgileadmedical.com

Adverse Event Reporting

Please report all adverse events to:

Gilead Global Patient Safety ☎ 1-800-445-3235, option 3 or www.gilead.com/utility/contact/report-an-adverse-event

FDA MedWatch Program by ☎ 1-800-FDA-1088 or ✉MedWatch, FDA, 5600 Fishers Ln, Rockville, MD 20852 or www.accessdata.fda.gov/scripts/medwatch

Data Privacy

The Medical Information service at Gilead Sciences may collect, store, and use your personal information to provide a response to your medical request. We may share your information with other Gilead Sciences colleagues to ensure that your request is addressed appropriately. If you report an adverse event or concern about the quality of a Gilead or Kite product, we will need to use the information you have given us in order to meet our regulatory requirements in relation to the safety of our medicines.

It may be necessary for us to share your information with Gilead's affiliates, business partners, service providers, and regulatory authorities located in countries besides your own. Gilead Sciences has implemented measures to protect the personal information you provide. Please see the Gilead Privacy Statement (www.gilead.com/privacy-statements) for more information about how Gilead handles your personal information and your rights. If you have any further questions about the use of your personal information, please contact gilead.privacy@gilead.com.